SGHT
Sight Sciences, Inc.8.39
+0.08+0.96%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A details Dry Eye constraints, glaucoma workflow
Q&A fleshed out Dry Eye's prudent ramp, pegging 0.1% penetration in two MACs (10.4 million covered lives, 700,000 patients), constrained by commercial infrastructure rather than assumed extra reimbursements. Management detailed a cataract-like workflow and half-dozen specialists to activate underpenetrated stand-alone glaucoma (mid-teens mix for them). They nodded to 2028 adult goniotomy reimbursement pressure but touted OMNI's MIGS edge as a buffer. Storms dinged Q1 glaucoma. Dry Eye's at 0.1% penetration. Answers reaffirmed scripted momentum, with confident yet cautious tone on execution. Investors will track MAC wins and stand-alone traction.
Key Stats
Market Cap
443.59MP/E (TTM)
-Basic EPS (TTM)
-0.90Dividend Yield
0%Recent Filings
8-K
10-K
FY2025 results
Sight Sciences posted FY2025 net loss of $38.4M, improved from $51.5M in FY2024, with revenue dipping 3.1% to $77.4M amid Interventional Glaucoma holding steady at $75.7M while Dry Eye plunged 58.7% to $1.6M. Q4 saw Dry Eye sales accelerate on new MAC pricing for CPT 0563T, yet Glaucoma faced headwinds from Medicare LCDs curbing multiple MIGS combos, trimming claims volumes. Gross margins edged up to 86.2% despite China tariffs; operating loss narrowed 26.6% to $37.1M via 20% headcount cut yielding $15M opex savings. Cash burned $29.7M to $92.0M, shoring liquidity with $40M debt at 10.35%. Reimbursement volatility threatens quarterly momentum.
8-K
Q4 growth, 2026 guidance issued
Sight Sciences reported Q4 2025 revenue of $20.4M, up 7% YoY, with full-year $77.4M down 3% amid flat glaucoma and plunging dry eye sales. Gross margins held steady at 87% quarterly, 86% annually, while operating expenses plunged 25% to $21.5M. Cash burn slowed sharply. Guidance eyes $82M-$88M revenue in 2026. Dry eye rebounds.
8-K
Q4 revenue up 7%
Sight Sciences released preliminary Q4 2025 results on January 13, 2026, showing total revenue of $20.3-20.4 million, up 7% year-over-year, driven by 130% Dry Eye surge to $0.7 million despite flat Surgical Glaucoma. Full-year revenue dipped 3% to $77.3-77.4 million, with cash at $92 million after $0.4 million Q4 burn. Dry Eye reimbursement wins fuel growth outlook. Results remain unaudited.
IPO
Employees
Sector
Industry
ALC
Alcon Inc.
79.02-0.17
ESMC
Escalon Medical Corp.
0.14+0.00
GKOS
Glaukos Corporation
113.76+2.03
HSCS
HeartSciences Inc.
2.31-0.16
IRIX
IRIDEX Corporation
1.00+0.02
LNSR
LENSAR, Inc.
12.06+0.54
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00
RXST
RxSight, Inc.
12.76+0.24
SENS
Senseonics Holdings, Inc.
6.62-0.17
STAA
STAAR Surgical Company
24.80+1.24